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Abstract
Recombinant virus-like particles (VLP) antigenically similar to rabbit hemorrhagic disease virus (RHDV) were recently
expressed at high levels inside Pichia pastoris cells. Based on the potential of RHDV VLP as platform for diverse vaccination
purposes we undertook the design, development and scale-up of a production process. Conformational and stability issues
were addressed to improve process control and optimization. Analyses on the structure, morphology and antigenicity of
these multimers were carried out at different pH values during cell disruption and purification by size-exclusion
chromatography. Process steps and environmental stresses in which aggregation or conformational instability can be
detected were included. These analyses revealed higher stability and recoveries of properly assembled high-purity capsids
at acidic and neutral pH in phosphate buffer. The use of stabilizers during long-term storage in solution showed that
sucrose, sorbitol, trehalose and glycerol acted as useful aggregation-reducing agents. The VLP emulsified in an oil-based
adjuvant were subjected to accelerated thermal stress treatments. None to slight variations were detected in the stability of
formulations and in the structure of recovered capsids. A comprehensive analysis on scale-up strategies was accomplished
and a nine steps large-scale production process was established. VLP produced after chromatographic separation protected
rabbits against a lethal challenge. The minimum protective dose was identified. Stabilized particles were ultimately assayed
as carriers of a foreign viral epitope from another pathogen affecting a larger animal species. For that purpose, a linear
protective B-cell epitope from Classical Swine Fever Virus (CSFV) E2 envelope protein was chemically coupled to RHDV VLP.
Conjugates were able to present the E2 peptide fragment for immune recognition and significantly enhanced the peptide-
specific antibody response in vaccinated pigs. Overall these results allowed establishing improved conditions regarding
conformational stability and recovery of these multimers for their production at large-scale and potential use on different
animal species or humans.
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Introduction
Rabbit hemorrhagic disease (RHD) has for many years been
responsible for the death or the slaughtering of free-living and
domestic rabbits in different regions of the world [1]. The disease
has become endemic in several countries and has also spread
outside the original regions of appearance [2–6]. RHD provokes
high mortality rates and a high number of pathologies in adult
rabbits [7,8]. The etiological agent is the rabbit hemorrhagic
disease virus (RHDV), a non-enveloped and icosahedral calicivirus
with a capsid mainly composed of the structural protein VP1
(VP60), of approximately 60 kDa [9].
During almost two decades, several approaches have been
conducted to express the RHDV capsid protein in heterologous
hosts or viral vectors aiming to reach a definitive non-conventional
vaccine [10–24] that could also end animal welfare issues related
with virus propagation in rabbits for vaccine preparation.
However, only some of the systems assayed have genuine potential
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for the production and eventual licensing of a veterinary vaccine,
a fact that depends on a great number of factors that include
safety, technological, financial and policy issues.
Following the first outbreaks of RHDV in the Americas, our
group directed research capabilities toward the development of
a scalable production platform in order to ease the field
introduction of a recombinant vaccine against RHD. Preceded
by successful examples of subunit vaccine production and
application in human and veterinary massive vaccination
programs [25–27] one Pichia pastoris mutant strain was selected
for the expression at high levels of the capsid protein from RHDV
[22,28]. The antigen was obtained forming soluble virus-like
particles (VLP) inside the yeast cells with high antigenic re-
semblance to RHDV and attractive levels for a simple and
inexpensive production process. At present, VLP vaccines against
pathogens such as the human papillomavirus have been licensed
and are commercially available [29].
The production of VLP for vaccination purposes should take
into account some requirements related with structural integrity as
stabilization of conformational epitopes and preservation of the
multimeric state during large-scale purification, formulation or
storage [30]. Bearing in mind these remarks we evaluated the
structure of these VLP and characterized them during these
processes under different conditions. Measurements of recoveries
were carried out after each step and after stresses that had been
shown to induce protein aggregation or conformational instability,
thus allowing the establishment of optimal process conditions. The
vaccine emulsions were also studied for their physical properties
and antigen integrity after thermal stresses. A production process
with high recovery levels is here proposed, developed, and
validated through the evaluation of protective capacity. Potential
stabilizers for these VLP were identified.
Recent investigations have also shown the significance of
RHDV VLP obtained from cultured cells for the incorporation
of foreign T-cells epitopes by genetic fusion or chemical
conjugation and the generation of humoral and cell-mediated
specific responses [31–34]. Therefore, an additional experiment
was accomplished to investigate their feasibility as carriers of a B-
cell epitope from Classical Swine Fever Virus (CSFV), an
important disease in swine responsible for a highly contagious
and fatal multisystemic disease that negatively impacts both animal
health and economic issues worldwide [35,36].
In our view, the pharmaceutically relevant improvements
attained regarding structural stability, along with the establishment
of a simple and inexpensive process for the large-scale production
of RHDV VLP antigenically similar to RHDV provide research-
ers and manufacturers with valuable data for the development of
carrier multimers for vaccination or therapeutic purposes. The
multimers produced in this robust vaccine manufacturing platform
have also the potential to become the first licensed yeast-derived
VLP veterinary vaccine.
Materials and Methods
Yeast and Virus Strains
Pichia pastoris PVP12 strain [22] allowed the production of the
recombinant VP1 multimers. VP1 obtained associated to the yeast
membranous system of P. pastoris PVP11 strain [28] was used for
comparative purposes in Western blot analyses. The RHDV
Italian Reference strain Bs.89 (X87607) was used in competition
enzyme linked immunosorbent assays (cELISA) while RHDV
CUB5-04 strain (DQ841708) or the Spanish AST/89 isolate
(Z49271) were employed in hemagglutination inhibition experi-
ments. The latter strain was also used for the challenge of rabbits.
Yeast Growth and Cell Disruption Procedures
The culture medium and growing conditions in the bioreactor
were set essentially as previously described to induce VP1
production [28]. For disruption, the pellet was resuspended at
350 g L21 (wet weight) in 50 mM phosphate buffer. A range of
pH and different concentrations of NaCl were assayed. The
disruption process was basically as described [28]. The raw
disruption supernatant was clarified by a centrifugation step at 10
000 g, 4uC, and filtration through 0.2 mm.
Purification of RHDV VLP by Size-exclusion High
Performance Liquid Chromatography
For analytical purposes a size exclusion high performance liquid
chromatography (sec-HPLC) TSK G5000 PW column
(600 mm67.5 mm) was used, equilibrated with phosphate buffer
at a flow rate of 0.6 ml min21. For purification of VLP at
preparative scale a TSK G3000 PW column (1000 mm667 mm)
and a flow rate of 0.4 ml min21 were employed. Detection was set
at 280 nm and most profiles were acquired and processed using
the LaChrom D-7000 HPLC System Manager v.3.1. The analysis
of particle integrity purified under different buffer conditions or
subjected to physical/thermal stressing treatments was also carried
out by sec-HPLC. Prior to analytical experiments, VP1 was
quantified in order to set an injection volume of 250 mL and
sample concentration of 0.25 mg/mL.
Production and Characterization of RHDV VLP
Purification of RHDV VLP on Sepharose CL4B. For scale-
up or purification of larger quantities of RHDV VLP, a XK26/35
column (350 mm626 mm) packed with Sepharose CL4B (Sigma,
USA) was used, equilibrated with phosphate buffer at the
appropriate pH. For production of active raw material starting
from 10-L bioreactions a 1000 mm6300 mm column was used at
flow rates of 5 mL/min.
Separation of RHDV VLP by Ultrafiltration. For com-
parative purposes, recombinant VLP were separated in a parallel
experiment by tangential ultrafiltration using a SartoconH Slice
200 ultrafiltration system having a Hydrosart membrane with
a molecular weight cut-off of 300 kDa (Sartorius, Germany).
Influence of pH on the conformational stability and
recovery of VLP during cell disruption, purification and
post-purification steps. We tested a broad range of pH (3.0,
4.0, 5.0, 6.0, 7.0, and 8.0) during cell disruption and purification
for their influence in aggregation, conformational distortion and
loss in VLP final recovery. After cell disruption and size exclusion
chromatography of the supernatant, VLP were subjected to a 10-
fold concentration step using 300 KDa cut off membranes
combined with diafiltration (changing three times the phosphate
buffer volume) in a SartoconH Slice 200 ultrafiltration apparatus,
followed by centrifugation at 10000 g, 0.2 mm filtration, and
quantification. Alternatively, three rounds of freezing/thawing
were conducted after filtration. In all steps the recovery was
determined. The experiments were performed in duplicate. Once
the conditions regarding pH were evaluated an analysis on ionic
strength and its influence on VLP recovery was performed.
Different concentrations of NaCl (0.1, 0.3, 0.5, 0.7, 0.9 and 1 M)
in the purification buffer were tested.
Screening of stabilizers for inhibition of protein
aggregation and instability during storage. Various poten-
tial stabilizers generally recognized as safe (GRAS) were screened
for their ability to prevent VLP aggregation and loss of protein
from the final solution. To evaluate the efficacy of the excipients
used, measurements of recovery were performed after purification,
freezing/thawing, sterile filtration and storage at 4uC for a time
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period of twenty four weeks. A control lot containing VLP in
phosphate buffer 0.3 M NaCl, pH 7.0 without excipients was used
for comparison. The additives used were: tween 20 (0.05 and
0.01%) sodium citrate (0.1, 0.2 M), and sucrose, trehalose, sorbitol
and glycerol (at 10 and 20%). The experiments were conducted
using duplicate lots in each case.
Equilibrium density gradient centrifugation. The study
of particles integrity in equilibrium sucrose density gradients was
conducted in duplicate as previously described [22].
Detection of VLP epitopes. The antigenic characterization
of the VLP was conducted by sandwich ELISA using a panel of
horseradish-peroxidase conjugated monoclonal antibodies direct-
ed against RHDV conformational epitopes, supplied by the OIE
(Office Internationale des Epizootes) reference laboratory for
RHD (Brescia, Italy). The characteristics of the mAbs are as
follows: mAb 1H8 recognizes an external, protective epitope
present only in correctly assembled RHDV, and absent in
aberrant or disassembled capsids. MAb 6F9 recognizes another
protective epitope in RHDV. MAbs 6H6 and 5B2 recognize
conformational surface epitopes present in monomeric VP1. MAb
6G2 is directed against a buried epitope located at VP1 N-
terminal portion. The mAbs working dilution was 1:500. In
sandwich ELISA, hyperimmune serum diluted 1:500 against
RHDV AST/89 was used for coating the plates. Identical
quantities of VP1 (one microgram per well) were loaded for the
analysis of surface epitopes. The assays were performed in
duplicate for the different samples analyzed. If needed, the
presence of heterogeneous VP1 populations was verified employ-
ing mAb 6H6.
Quantification. The expression levels of VP1 were measured
by sandwich ELISA using anti-RHDV hyperimmune serum at
a dilution of 1:3500 as capture antibody, the monoclonal antibody
6H6 (dilution 1:500) for antigen detection, and a curve of different
known concentrations of standard VP1 from insect cultured cells
[23]. For quantification of assembled VLP the monoclonal
antibody 1H8-HRP conjugate was used. Reactions were de-
veloped for 3–5 min in the dark using 0.4 mg mL21 orthophe-
nylenediamine (OPD) (Sigma, St. Louis, USA) diluted in 0.005 M
citric acid/0.1 M Na2HPO4 containing 0.015% H2O2 (BDH,
UK). The reaction was stopped with 50 mL per well of 2.5 M
H2SO4. Measurements were performed at 492 nm in a SensIdent
Scan ELISA reader (Merck, Germany).
Vaccine Formulation
VLP were quantified and the final solution was sterilized by
filtration. The oil-based adjuvant Montanide 888 VG (SEPPIC,
France) was mixed in sterile mineral oil at a ratio of 1:9. A water-in
oil emulsion was prepared at a proportion of 40% oil phase and
60% aqueous phase using the homogenizer ULTRA-TURRAX
T25 basic (IKA Works Inc., NC). Depending on the experiment
accomplished, vaccines were formulated as 5, 10, 25 and 50 mg in
a final volume of 1 mL per dose. They were filled manually under
sterile conditions in glass bottles of 20 mL.
Mechanical Stability
To determine the stability of the emulsion by gravitational
force effects, 10 mL of emulsion were poured into two 15 mL
centrifuge tubes. The height of the emulsified column (Ho) was
measured in the tubes and then they were centrifuged in
a 30 cm radius centrifuge for 1 hour at 3000 rpm. The
emulsified column height was measured again (Hu). The ratio
Hu/Ho was calculated. Only if this relation was equal to or
higher than 0.8 the sample was considered to fulfill quality
parameters of production.
Thermal Stress Experiment
Samples of vaccine formulations were incubated for 7 days at
4uC, 37uC, 48uC or 60uC, until further studies.
Thermal stability. The height of the emulsified column (Ho)
was measured prior to the stresses. Then, only the emulsified
column was measured again (Hu). The Hu/Ho ratio was
calculated. Only if the relation was equal to or higher than 0.9
it was considered that the sample fulfilled the quality parameters.
Viscosity and organoleptic characteristics
determination. Viscosity measurements for the formulated
samples subjected to thermal stress were recorded at days 0 and
7 using a rotational rheometer. A cp 40 spindle was used and the
gradient speed employed was of 2, 4, 6, 8 and 10 rpm. A visual
evaluation of organoleptical characteristics from each sample was
carried out. The study was performed at 25uC.
Emulsion separation. VLP/Montanide 888 VG emulsion
samples of 1 mL each were frozen at 220uC for 12 h. After
centrifugation at 10 000 g for 30 min the samples were separated
in two phases; an aqueous phase (translucent) and a semi-oil phase
(white). The aqueous phase was extracted and stored at 220uC.
For the analysis of the VLP surface epitopes within the aqueous
phase, one microliter was used in ELISA.
Transmission Electron Microscopy
The morphology and size of RHDV VLP in samples purified at
different pH values or subjected to thermal stresses was examined
by transmission electron microscopy (JEOL JEM 2000 EX, Japan)
as already described [22].
CSFV Peptide Coupling to RHDV VLP
Peptide synthesis. The 24th amino acids CSFV E2 peptide
(H2N-KEDYRYAISSTNEIGLLGAEGLTC-COOH) was syn-
thesized at analytical scale using the Fmoc/tBu strategy [37]
at the Peptide Synthesis Laboratory of CIGB. It was purified by
RP-HPLC and characterized by mass spectrometry. The mass
spectrum was acquired in a hybrid Q-Tof -2TM mass
spectrometer from Micromass (UK) equipped with an ESI Z-
spray ion source. The software for acquisition and processing of
the mass spectra was MassLynx, v4.0 (Waters, USA). Peptide
RP-HPLC purity grade was of 95% and its identity was
confirmed by comparison with the theoretical value for this
amino acids sequence.
Coupling to the carrier protein. A Cysteine amino acid
coupled at the C-terminal of the peptide sequence was used as
a convenient handle for peptide conjugation to the carrier
protein. Briefly, VP1 was dissolved in phosphate buffer solution
pH 6.0 and a 10 mg/mL solution of M-maleimidopropionyl-N-
hidroxysuccinimide esther (MPS) in N,N-Dimethylformamide
(DMF), was added. The reaction was stirred during 30 min at
room temperature. Free MPS was separated from MPS-
activated protein by dialysis against phosphate buffer solution
pH 6.0 at 4uC. Then, CSFV E2 peptide dissolved in phosphate
buffer solution pH 6.0 was added to the previously activated
protein and the reaction was stirred for 3 hours at room
temperature. Free CSFV E2 peptide was separated from the
peptide conjugated protein by dialysis against PBS (pH 7.2) at
4uC. Both dialysis steps were performed with a Spectra/PorH
molecular porous membrane (MWCO 12–14 000) from
Spectrum Laboratories, Inc. (USA & Canada). Total protein
content was determined by the Lowry method [38]. Charac-
terization of CSFV E2 peptide attachment to VP1 was carried
out by analysis in SDS-PAGE and sec-HPLC.
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Immunization Trials
Animals. New Zealand female rabbits of 8 weeks age and
approximately 2 Kg weight, seronegative to RHDV (as de-
termined by ELISA) were used in all the experiments. Eight to
10 weeks old Duroc/Yorkshire crossbreed male pigs, serologically
negative to CSFV and belonging to a non-vaccinated and CSF
free herd were also used. All the studies involving experimentation
with animals were in accordance with guidelines and recommen-
dations from the Guide for the Care and Use of Laboratory
Animals (current Edition) and policies from the Cuban Society of
Laboratory Animals’ Science (SCCAL). The experimental proto-
cols were drafted by the authors and approved by the Animal
Welfare Commission of the Bioterio Division from the Center for
Genetic Engineering and Biotechnology. In all cases, supervision
of veterinary authorities from the Institute for Veterinary
Medicine, Havana, Cuba was guaranteed. When rabbits or pigs
were used for experimentation, they were housed in individual
rooms and appropriate feeding, water supply and health
monitoring was permanently provided. Animals euthanized were
humanly handled. They were subjected to initial anesthetization
and potassium chloride injection intravenously to avoid suffering
after challenge. Pigs were also carefully monitored for body
temperature and any signs of immunization reactions.
Serum samples procedure. Blood samples were extracted
from the marginal ear vein of rabbits at days 0, 14, 21, 40, and also
at 60, 90 depending on each trial, in order to analyze the titers,
specificity and time-course of antibodies generated against RHDV.
In trial II, serum samples were taken to survivors 10 days after
challenge.
Experiment I: Immunogenicity of the formulation
subjected to thermal stress. Six groups of six rabbits each
were immunized with vaccine formulations treated at 4uC, 37uC,
48uC or 60uC for one week, respectively. The animals received
two subcutaneous doses containing 50 mg of the protein at days
0 and 21. The experiment included a negative control group that
was simultaneously injected with Montanide 888 VG as placebo
and a group immunized with the vaccine formulated at the time of
use.
Experiment II: Protective efficacy. Three groups compris-
ing one group of seven rabbits and two groups of three rabbits
each were immunized as follows: Group I (seven rabbits) was
immunized with two doses containing 50 mg of the VLP. The
second group was vaccinated with 50 mg of VP1 expressed in Sf9
cultured cells using the baculovirus expression system, and
a negative control group was injected with Montanide 888 VG.
Rabbits were injected via subcutaneous at days 0 and 21. At day
40 they were intramuscularly challenged with a lethal dose of
approximately 100 LD50 (16 000 HA units) of the AST/
89 RHDV strain. Challenged animals were monitored for clinical
symptoms of the disease.
Experiment III: Minimal protective dose. An experiment
was designed to investigate the minimum dose and the number of
vaccine inoculations needed to achieve the protective response.
Seven groups of six rabbits each were subcutaneously immunized
with vaccines formulated to contain different quantities of VLP:
From groups 1 to 4, rabbits were injected with two doses separated
by 21 days. Group 1 received 50 mg, group 2 was immunized with
25 mg, group 3 was injected with 10 mg and group 4 received doses
of 5 mg. Groups 5 and 6 were immunized with a single dose
containing 50 and 25 mg, respectively while a sixth group was
solely injected with Montanide 888 VG as placebo.
Experiment IV: Immunization with RHDV VLP-E2
peptide conjugate. This experiment was identically carried
out in rabbits and pigs. Five groups of five animals each were
randomly generated and immunized as follows: All vaccine
preparations were emulsified in Montanide 888 VG in a final
volume of 1 mL; all animals were immunized by intramuscular
injection in the neck (pigs) or the back (rabbits) and doses were
administered two weeks apart. Group 1 received 50 mg of
unconjugated RHDV VLP as placebo. Group 2 was immunized
with 50 mg of the entire E2 recombinant protein purified from the
milk of non-transgenic goats [39]. Group 3 was injected with
50 mg of monomeric E2 peptide. Group 4 was vaccinated with
50 mg of unconjugated VLP co-formulated with 50 mg of the
soluble E2 peptide. Group 5 was vaccinated with 50 mg of RHDV
VLP carrying the E2 peptide fragment attached by chemical
conjugation. Sites of injection and animal health status were
monitored daily.
RHDV Antibody Assays
Competition enzyme-linked immunosorbent assay. Sera
from rabbits were evaluated at a single dilution (1:10) with
a competition ELISA for RHD [40] manufactured at the OIE-
Reference Lab, Italy, implemented as previously described [22].
Sera were considered negative when the absorbance value at
492 nm decreased by less than 15% with respect to the reference
value (average of negative control sera) and positive if they
decreased by 25% or more (OIE Terrestrial Manual, 2010).
Hemagglutination inhibition assay. Serum hemagglutina-
tion inhibition (HI) titers were measured as already described [22].
Positive controls (sera from rabbits immunized with inactivated
RHDV CUB5-04) and negative controls (sera collected from
seronegative rabbits) were included. The HI titer of each sample
was expressed as the reciprocal of the highest dilution at which no
hemagglutination was observed.
Detection of Peptide and E2 Specific IgG Antibodies by
ELISA
In brief, to determine antibody levels against E2 whole protein
or E2 peptide in rabbits or pigs serum, PolySorp F96
immunoplates (Nunc, Denmark) were coated for 12 h at 4uC
with 100 mL per well containing 1 mg of the appropriate antigen in
0.1 M carbonate buffer, pH 9.6. Plates were washed and blocked
with 2% skim milk (Oxoid, UK) for 1 hour. One hundred mL of
serum from each animal was added at a dilution 1:10 in PBS and
serially diluted two fold in replicate wells for titration. Plates were
incubated, washed, and 100 mL of goat anti-rabbit or rabbit anti-
swine IgG-horseradish peroxidase conjugates (Sigma-Aldrich,
USA) diluted 1:10000 in PBS were added to each well. Reactions
were developed with OPD and read at 492 nm. Titers were
expressed as the inverse of the maximum serum dilution having an
OD superior to the negative control mean OD. A modified
cELISA was adapted to detect anti-RHDV VLP IgG antibodies in
serum of immunized pigs by addition of swine serum for
competitive analysis.
Statistical Analysis
Mean antibody titers, mean absorbance values or mean
inhibition values were obtained from serum of individual animals,
according to each experiment described. If applicable, an analysis
of variance was employed for each time point and mean values
were compared using the Newman-Keuls Multiple Comparison
test. Otherwise, values were compared with the Kruskal–Wallis
and the Dunn’s tests. The tests were carried out using the statistical
software GraphPad Prism v4.0.
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Results
Variations to pH, Ionic Strength and the Use of Additives
Influence the Stability and Recovery of RHDV VLP during
Cell Disruption, Purification and Storage
The structure of multimers antigenically similar to RHDV
obtained in P. pastoris was analyzed at different pH values during
cell disruption and purification at a temperature of 25uC.
Quantifications of the VLP were conducted at various stages
considering that some stressing steps were previously shown to
induce aggregation phenomena or conformational instability.
Structure preservation of the VLP during storage in solution was
also examined with the use of stabilizers with potential value in
a large-scale production process.
Through the evaluation of a range of pH from 3 to 8 different
chromatographic profiles were recorded by sec-HPLC using
a TSK G3000 PW preparative column. In the process assayed,
clarified disruption supernatant from yeast cells was taken as
starting material. The VLP were first quantified followed by
a single chromatography step, concentration/diafiltration, sterile
filtration, re-quantification and conformational analysis. Other-
wise, three rounds of freezing/thawing were included in the
process followed by sterile filtration and antigenic studies.
Measurements of the final recovery were conducted.
The highest quantities of multimers measured after purification
and concentration were found at pH 4 and 7 with recoveries of
about 84 and 88%, respectively. One homogeneous, undistorted
narrow peak corresponding with RHDV VLP at a retention time
of approximately 16 min was seen in both cases, as detected with
mAb 1H8. On the opposite, the chromatography pattern varied
the most at pH 8 showing a minor peak and fewer particle yields.
High to moderate recovery levels were obtained at pH 6, 3 and 5,
with a decrease in that order (Table 1). Some variations with
respect to the profiles obtained at pH 4 and 7, consisting on
heterogeneity due to the presence of more than one population of
VP1 were also seen, mostly at pH 5 (Figure 1A). The decrease in
recoveries of the multimers at some pH values was attributed to
the formation of insoluble aggregates. In the purifications carried
out, after concentrating the volumes recovered from the chroma-
tography column and once more after freezing and thawing, small,
insoluble white flocks could be visualized and separated by
centrifugation or filtration. The presence of VP1 in those fractions
was corroborated by ELISA and immunodot. Insoluble VP1
without its proper conformation accounted for about two thirds of
the protein quantified while VP1 with native unaffected epitopes
accounted for approximately one third. These solutions, which
became more opalescent to the eye, produced a substantial light
absorption increase in turbidity measurements conducted at
380 nm (not shown). Aggregation was also induced and confirmed
in turbidity measurements carried out at 60uC. Finally, after
freezing/thawing stresses, the processes at pH 4 and 7 rendered
the highest recoveries of assembled capsids, with values over 40
and 45%, respectively (Table 1).
To further characterize changes induced by pH, we examined
the morphology of the multimers, as well as the preservation of
surface epitopes which are relevant for the proper tertiary and
quaternary state of the protein. After transmission electron
microscopy (TEM), the multimeric structures seemed predomi-
nantly invariant in the pH range 3–7 showing an structure with
diameters of around 30–40 nm in most cases (Figure 1B). At
pH 8, fewer particles were distinguished, suggesting that the
alkaline pH started to induce changes in VP1 quaternary
structure. The latter results were consistent with buoyant densities
recorded, in which values closer to the buoyant density of
authentic VLP were achieved at pH from 3 to 8, with the closest
values (1.31–1.32 g/mL) at pH 4–7. Conformational epitopes
were also detected by monoclonal antibodies 1H8, 6F9, 6G2 and
5B2 with a variety of recognition degrees that were in accordance
with the results obtained by means of the other techniques. The
RHDV VLP produced at pH 7 were also characterized by SDS-
PAGE and Western blot analysis (Figure 1C). The multimers
obtained at pH 4 and 7, as well as native virions (Bs.89 strain) used
as positive control were identically recognized by the mAbs above
mentioned (Figure 1D).
Variations to the ionic strength of the buffer species selected
(sodium phosphate) and their influence on VLP stability suggested
that a concentration of 0.3 M NaCl is the most appropriate in
terms of final recovery. This analysis was conducted at pH values
of 4 and 7 (Table 2). After that, a number of excipients were
evaluated at different concentrations for their ability to prevent
aggregation or destabilization of the VLP structure during a 24
week storage period at 4uC (pH 4 and 7). Under such conditions,
a similar event of protein loss had been observed. Although the
margin of variation was to some extent narrow, the results
indicated that sucrose 20%, sorbitol 20%, glycerol 20%, trehalose
20% and 0.2 M sodium citrate were at different degrees useful
stabilizing agents in comparison with the use of no additives during
long-term storage in water buffered solution. According to the
experiment, when no additives were used a recovery of
approximately 50% is encountered. In summary, phosphate buffer
containing 0.3 M NaCl at either pH 4 or 7 can be used to obtain
major recoveries of multimeric VP1.
The Vaccine Formulation Containing the Recombinant
VLP Remained Physically and Thermally Stable after an
Accelerated Thermal Stress Experiment
RHDV VLP were formulated in Montanide 888 VG. The
emulsion obtained after mixing complied with the Oswald model
for non-Newtonian fluids, with viscosity-index values (m)
,1500 mPa/s and flow-index values (n) between 0.5 and 0.9.
The formulated vaccines were subjected to an accelerated thermal
stress treatment and then studied for the physical properties of the
emulsion and integrity of the multimers.
The physical stability of the formulations was first assayed
through viscosity analyses. In those emulsions kept at 37uC or
48uC for 7 days, this parameter was significantly lower than that of
the emulsion maintained at 4uC. The emulsion stored at 4uC had
a similar, although a slightly higher viscosity than the vaccine
emulsified and evaluated immediately after formulation, which
was used as a control (Figure 2). On the other hand, the emulsion
incubated at 60uC became separated into two phases. No
differences were observed in the organoleptical characteristics of
the unseparated emulsions, which at the end of the experiment
showed a non-Newtonian fluid behaviour, as oil-based formula-
tions do.
VLP were extracted from the emulsions treated and analyzed by
sec-HPLC. In the samples treated, a reduction in the intensity of
the signal corresponding to VLP was noticed although retention
times remained invariable (Figure 3A). An increment in the
homogeneity of the high molecular weight structures from samples
kept at 48 and 60uC was observed while an increment in late
signals, attributed to dissociated capsids and not to degradation,
was detected for samples subjected to these temperatures.
The appearance and structure of the multimers was analyzed by
TEM and no evident changes were seen in samples incubated at 4,
37 or 48uC. In samples kept at 60uC, small quantities of assembled
high molecular weight structures were observed (Figure 3B).
Results from density gradient centrifugation experiments of
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Figure 1. Analysis of the RHDV VLP purified under different conditions. (A) Chromatographic profile of RHDV VLP after disruption and
purification conducted at different pH values. Purification was performed by sec-HPLC using a TSK G-3000 preparative column. In all cases multimeric
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samples treated at 37 and 48uC revealed a slight decline of VLP
concentration in those fractions with buoyant densities close to
that of RHDV. This decline became clear at 60uC. Changes in the
quaternary structure of VLP stressed at this last temperature were
apparently irreversible. However, the study on the preservation of
conformational epitopes revealed minor variations in the reactivity
of mAbs 1H8, 6F9, 6H6, 5B2 and 6G2 in samples incubated at 37
or 48uC. As expected, the epitopes recognized by these mAbs were
hardly detected in the sample kept at 60uC (Figure 3C). These
experiments demonstrated that differences can be found; nonethe-
less the vaccine formulations remain stable at temperatures of 37
and 48uC. As later evidenced in animal experiments, the slight
variations in the conformational structure of the VLP within these
formulations were not significant in terms of immunogenicity.
Size-exclusion Chromatography on Sepharose CL4B is an
Efficient Approach for the Large-scale Production of
RHDV VLP
Recombinant RHDV VLP could be purified and processed in
accordance with the previous findings in order to obtain the
highest recovery and stability levels. Laboratory-scale procedures
and analytical techniques were selected and summarized in view of
the process scale-up. Then, 10-L culture bioreactions were carried
out as two independent lots. Depending on their characteristics,
the subsequent operations were also scaled-up. Production of VP1
multimers was in accordance with the seed-batch principle, in
which the recombinant strain is maintained as a master seed bank
(MSB) and working cell bank (WCB) and are both stored in
individual vials at 270uC. The stock is stored for many years and
each new culture starts from the same original seed preparation.
These cell banks comply with sterility and viability tests performed
periodically, showing 106 cells/mL in every determination.
For purification scale-up, separation of the VLP was performed
by gel filtration chromatography using Sepharose CL4B. Tan-
gential ultrafiltration of clarified supernatant using the SartoconH
Slice 200 ultrafiltration system with a membrane with a molecular
weight cut-off of 300 kDa was carried out in parallel for
comparative purposes. Interestingly, purity of ordered multimers
obtained in the single chromatography step was over seven times
higher (72.04 versus 10.2) than purity achieved by ultrafiltration
(Figure 4A). The total of proteins in the first peak was determined
by the Lowry method [38], followed by quantification of RHDV
VLP by ELISA using the monoclonal antibody 1H8 (Figure 4B).
In this way, VP1 quantities are only referred to properly assembled
capsids. In the first peak, a minor amount of heterogeneous VP1
detected with monoclonal antibodies other than 1H8 accounted
for the rest of the protein purified while alcohol oxidase from P.
pastoris appeared as a faint band migrating at approximately
75 kDa. The elution of lower molecular mass proteins and yeast
components was obtained as a highly dense yellow solution in the
last fractions. As suggested in the Test Procedures and Acceptance
Criteria for New Biotechnological/Biological Veterinary Medic-
inal Products from the International Cooperation on International
Harmonization of Technical Requirements for Registration of
Veterinary Medicinal Products (VICH), heterogeneous VP1 was
considered as a product-related substance. Then, VLP were finally
separated in Sepharose CL4B following process hints and
established manufacturing practices approved for the large-scale
production of the licensed recombinant GavacplusTM vaccine
[41,26]. The disruption and purification steps were carried out in
one day and allowed producing active raw material equivalent to
approximately 50000 doses per bioreaction. At the end, samples
were tested for sterility and potency in mice and rabbits taking
cELISA and HI assays as tests to comply (not shown). The process,
developed until formulation and filling, was conducted with good
reproducibility and set the bases for larger production. A flux
diagram of the nine steps procedure was established (Figure 4C).
The aqueous part of the final formulation consisted of phosphate
VP1 was detected in the first peak and quantified by sandwich ELISA using monoclonal antibodies. Retention times are indicated. (B) Electron
micrographs of negatively stained samples containing VP1 multimers obtained after separation in sec-HPLC. According to measurements by ELISA,
the highest recoveries were obtained at pH 4 and 7. The morphology and size of the VLP was analyzed by TEM using 2% uranyl acetate for negative
stain. The bars indicate 200 nm. Magnifications: x30 000 and x40 000. (C) SDS-PAGE (lanes 1, 2) and Western blot analysis (lanes 3, 4) of purified VLP.
Lane 1 corresponds to disruption supernatant from P. pastoris PVP12 strain. Lanes 2 and 3 were loaded with purified RHDV VLP. A minor band
migrating close to 60 kDa was also detected in lane 3. For comparison, lane 4 shows glycosylated VP1 expressed associated to the yeast membranous
system in PVP11 strain, in which various protein bands were recognized by the hyperimmune serum. The molecular weight of approximately 60 kDa
is shown in the left and indicated by an arrow in the right. (D) Analysis with conformation dependent monoclonal antibodies of epitopes located on
the VLP obtained after cell disruption, purification, and rounds of stressing steps at pH values of 4 and 7. RHDV VLP and native RHDV were detected
using mAbs 1H8, 6F9, 5B2, and 6G2. Standard deviation bars of measurements performed are indicated.
doi:10.1371/journal.pone.0056417.g001
Table 1. Recovery of properly assembled RHDV VLP during the evaluation of different pH in the disruption and purification
processes.
VLP quantification [Mean 6 standard deviation (mg/mL, first row)/Percent of recovery (%, second, third row)]
Process stage pH 3.0 pH 4.0 pH 5.0 pH 6.0 pH 7.0 pH 8.0
Cell disruption, centrifugation, and filtration (0.2 mm) 452619.6 850635.3 415618.3 685625.1 820631.2 318612.0
Size exclusion chromatography, 10 fold concentration-
diafiltration, centrifugation, sterile filtration (0.2 mm)
57.566.4 84.265.6 43.264.8 68.567.0 88.565.1 44.864.1
Three rounds of freezing-thawing, sterile filtration
(0.2 mm)
3364.2 40.665.6 29.768.1 35.766.4 45.462.6 2463.5
Purification was performed by size exclusion chromatography using a preparative TSK G3000 column. Alternatively, an additional step known to induce instability and
protein aggregation (rounds of freezing-thawing) was included. Quantification of recovered VLP was accomplished by sandwich ELISA with the use of mAbs.
VLP directly detected after cell disruption and clarification were expressed in the first raw as mg per mL of disruption supernatant. Starting from those values, percents of
recovery are shown for the next two steps. All measurements were done in duplicate starting from two independent bioreactions. Protein amounts and percents of
recovery refer only to properly assembled VLP.
doi:10.1371/journal.pone.0056417.t001
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buffer 0.3 M NaCl, pH 7.0 containing the VLP, then adjuvanted
in Montanide 888 VG. Vaccine preparations complied with
mechanical and stability tests. Various trials were carried out in
order to complement the results described.
The Vaccine Formulations Assayed were Highly
Immunogenic in Vaccinated Animals
The first trial aimed to investigate the influence of the thermal
stresses applied to the VLP on their immunogenicity in rabbits.
After treatments to the formulations, rabbits were immunized at
days 0 and 21 with 50 mg of VLP. A cELISA was used to detect
specific anti-RHDV IgG levels. Except for the group immunized
with the vaccine treated at 60uC and re-formulated, all the animals
vaccinated with emulsions prepared at the time of use, or kept at 4,
37, or 48uC for one week, developed antibody levels correspond-
ing with inhibition percents over 85–90% in determinations
practiced at days 14, 21, 40, 60, and 90. No statistically significant
differences were found between them at each time point
investigated.
Rabbits for the challenge experiment were immunized under
the same schedule. Animals injected with insect cells-derived VP1
or placebo were included as positive and negative controls. All
animals were challenged 42 days after the first vaccination with
100 LD50 of RHDV. Prior to challenge, all rabbits receiving the
yeast-derived VLP and rabbits from the positive control group had
developed anti-RHDV specific antibodies with inhibition percents
over 90% and HI titers up to 1/1024. Titers slightly increased
after challenge in animals immunized with the yeast-derived VLP
up to values that ranged from 1/512 to 1/2048 (Table 3). Rabbits
receiving placebo died within the first 36 hours after challenge or
were euthanized to avoid suffering. Clinical symptoms of the
disease and visible lesions on spleen and liver during necropsy
were observed only in rabbits injected with placebo.
A further experiment explored whether a reduction in the
number of doses or in antigen quantities could elicit protective
immunity. Groups of rabbits were immunized twice with 5, 10, 25
or 50 mg of VLP. Two other groups were vaccinated with a single
VLP dose of 25 or 50 mg. HI assays and cELISA were used to
measure the immune responses. Rabbits injected twice with 5 or
10 mg of VLP were able to develop an antibody response with
inhibition percents over 85% in cELISA although protective HI
titers over 1/80 were not detected. In contrast, animals
immunized twice with 25 or 50 mg per dose showed inhibition
percents over 85% and protective HI values up to 1/512.
Interestingly, inhibition percents and HI titers elicited in rabbits
inoculated once with 50 mg of the VLP were similar to those
developed in animals immunized twice with the same dose. They
were also in the range of values from animals injected twice with
Table 2. Recovery of VLP obtained after buffer variations and with the use of stabilizers during storage.
Treatment VLP percent of recovery (%)
Purification in phosphate buffer, including
three rounds of freezing/thawing 0.1 M NaCl 0.3 M NaCl 0.5 M NaCl 0.7 M NaCl 0.9 M NaCl 1 M NaCl
At pH 4.0 35.7 44.8 42 40.4 42.9 43.2
At pH 7.0 23.4 46.5 32.7 34.1 29.8 31
Additives in the final storage volume (at 4uC,
pH 7.0 for 24 weeks)a
Tween 20 Sodium citrate Sucrose Trehalose Sorbitol Glycerol
0.05% 24.5
0.01% 10.5
0.2 M 56.2
0.1 M 28.0
20% 71.9 69.4 70.1 75.4
10% 48.4 49.0 47.5 55.6
aVarious excipients were evaluated at different concentrations during VLP in storage at 4uC for a time period of 24 weeks after purification. The initial concentration of
VLP in all samples was 500 mg mL21. The experiments were conducted using duplicated lots. The percent of recovery was calculated as the percent of aggregation
inhibition in the presence of additive = aggregation inhibition in the presence of additive * 100/concentration of aggregated proteins in the absence of additive where:
aggregation inhibition in the presence of additive = concentration of aggregated proteins in the absence of additive - concentration of aggregated proteins in the
presence of additive.
Similar results in terms of recovery were obtained at pH 4 or 7 with the additives assayed. For simplicity, only recoveries at pH 7.0 are shown.
As a control lot, VLP were kept in identical storage conditions without stabilizers in phosphate buffer pH 7.0, 300 mM NaCl. In such case, the recovery of VLP accounted
for a 48.5%.
doi:10.1371/journal.pone.0056417.t002
Figure 2. Evaluation of the apparent viscosity in a velocity
gradient of RHDV VLP vaccine samples treated at 4uC, 37uC,
and 48uC for 7 days. An emulsion sample taken immediately after
formulation was used as control. The average and standard deviation
bars for each experimental point are indicated. T0 = time 0.
doi:10.1371/journal.pone.0056417.g002
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25 mg, which in turn were similar to those detected in rabbits
vaccinated once with that dose (Table 4).
RHDV VLP were Able to Enhance the Immune Response
to a Protective Peptide Fragment from Classical Swine
Fever Virus (CSFV) E2 Envelope Protein
Amino acid sequence alignment between a linear B-cell
protective epitope from CSFV E2 glycoprotein (Shimen strain:
AF092448) [42] and its homologue region in the Cuban highly
pathogenic ‘‘Margarita’’ strain [43] was carried out. A peptide
fragment was designed in which two amino acid changes (positions
697 and 713) were introduced within the 24 aa sequence, and also
a cysteine residue placed at the C-terminal to direct coupling to
VP1 multimers. The peptide fragment was synthesized with purity
over 95% as corroborated by RP-HPLC and mass spectrometry.
Conjugation of the E2 peptide to RHDV VLP was achieved with
the use of M-maleimidopropionyl-N-hidroxysuccinimide esther.
Conjugates were obtained as result of the reaction between the
cysteine residue on the peptide and the maleimide-activated sites
on VP1. An excess of peptide (5 mg) was utilized for conjugation
to 5 mg of RHDV VLP. Once conjugation was accomplished,
samples were subjected to dialysis in order to separate and remove
possible unbound groups. Conjugation efficiency was visualized by
Figure 3. Analysis of the recombinant VLP extracted from vaccine formulations subjected to an accelerated stress treatment
experiment. (A) Analysis in size-exclusion HPLC. The temperature at which the emulsion was kept for one week and the retention times
corresponding to elution of multimeric VP1 are indicated in each chromatogram. The inner figures show Western blot analyses and detection of VP1
in the main peaks detected, which were designated as 1 and 2 according to their appearance in the chromatogram. An anti-RHDV hyperimmune
serum was used. The 60 kDa band is indicated. (B) Electron micrographs of negatively stained samples containing the extracted VLP. The VLP
structure was analyzed by TEM using 2% uranyl acetate. The bar indicates 200 nm. Magnification: x40 000. (C) Detection of RHDV VLP epitopes with
the conformational-sensitive monoclonal antibodies 1H8, 6F9, 6H6, 5B2, and 6G2 after thermal stresses. Standard deviation bars are indicated.
doi:10.1371/journal.pone.0056417.g003
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comparison between unconjugated and conjugated proteins.
Resulting conjugates showed a different pattern in SDS-PAGE
with various protein bands migrating close to each other with sizes
slightly superior than that of the unconjugated carrier (Figure 5A).
Both VLP accessibility and peptide recognition after conjugation
were corroborated with polyclonal antibodies obtained in mice
against the peptide fragment and with the monoclonal antibody
1H8 directed to RHDV. Interestingly, RHDV VLP conjugates
retained at least a partial binding affinity while the peptide was
effectively recognized.
An experiment was conducted in rabbits and pigs with quite
similar results in terms of specific IgG antibodies against the B-cell
epitope coupled to RHDV VLP. Groups of animals were
randomly created and immunized with 50 mg of conjugated
VLP, 50 mg of peptide, both antigens co-formulated or 50 mg of
an entire E2 recombinant protein [39]. No relevant uncommon
lesions were observed at the sites of injection and animals
maintained a healthy status during the experiment. An ELISA
was developed to evaluate the peptide specific antibody responses
after intramuscular immunizations administered two weeks apart.
Animals immunized with the E2 peptide fragment conjugated to
RHDV VLP showed the strongest IgG specific response that
became statistically superior with respect to the rest of the groups
after the second dose administered (Figure 5B, C). Pigs
vaccinated with the peptide alone, animals injected with the
soluble E2 peptide in addition to VLP, as well as the group
immunized with the entire E2 recombinant protein, developed
a similar though lower response against the peptide fragment. The
peptide-specific response appeared to decline in the measurements
performed by day 120, in which the differences between pigs
immunized with the E2 peptide conjugated to VLP and the other
groups were still marked. The humoral immune response was also
evaluated by ELISA using the complete E2 homodimeric protein
directly adsorbed onto the plates. The peptide-immunized groups
showed IgG levels slightly inferior to those generated in animals
vaccinated with the entire protein. Antibodies with the capacity to
compete for binding to RHDV were also detected by a modified
cELISA in vaccinated rabbits and pigs, as an additional indicator
of multimeric structure preservation (Figure 5D). Finally, a pre-
liminary assessment for CSFV-specific neutralizing antibodies,
according to [39], allowed detection of specific titers in three of the
five pigs immunized with the RHDV VLP-E2 conjugated peptide
after the second dose administered. These experiments showed the
ability of stabilized RHDV VLP produced from yeast to present
a viral B-cell epitope and enhance the specific immune response to
it in a large animal model as swine.
Figure 4. Purification scale-up of the recombinant RHDV VLP by size exclusion chromatography (SEC) on Sepharose CL4B, starting
from 10-L culture bioreactions. (A) Chromatography pattern of homogeneous high-purity VLP. The inner upper figure corresponds to
purification by tangential ultrafiltration (UF) using a membrane with a 300 kDa cut-off, showing low purity VLP. The inner lower figure shows SDS-
PAGE and electron micrograph of negatively stained samples containing VLP purified by SEC. Numbers in the left indicate the migration of standard
molecular weight markers. The bar indicates 200 nm. Magnification: x30 000. (B) Results obtained from the VLP production scale-up. (*) Total of
proteins measured by the Lowry method. (**) Properly assembled RHDV VLP quantified by ELISA. (C) Block diagram showing upstream and
downstream processes to obtain the recombinant VLP and to produce the vaccine at large-scale.
doi:10.1371/journal.pone.0056417.g004
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Discussion
It is known that several procedures result in stressing conditions
for recombinant proteins subjected to purification, formulation or
storage. Changes of pH, concentration of chaotropic agents,
crossings of solubility thresholds, exposure to solid and air
interfaces during concentration, centrifugation, filtration [44–
46], as well as the use of excipients, temperature and time of
storage, and freeze/thawing may promote structural changes
leading to missfolding, unexpected protein-protein associations
and aggregation.
In this work, we first analyzed the influence of pH during
production of multimeric VP1. We considered previous laboratory
evidence of process steps causing loss in VLP recoveries from
solution due to aggregation events. Combined approaches have
been also previously used to characterize multimeric antigens
derived from this yeast strain [47–49]. As seen in the experiments,
VLP in solution underwent changes that were dependent on pH.
The patterns, retention times and recovery values suggested major
stability in acidic to neutral pH, which was in part similar to
findings described for Norwalk virus (NV) VLP analyzed under
physical-chemical approaches [50]. NV VLP appeared more
stable in the pH range 3–7 with a maximal stability at pH 4–5.
The stability noticed for other calicivirus-like particles at acidic pH
has been attributed in part to the capacity in vivo of some of these
viruses to attach to the host gastrointestinal tract [50–52]. On this
matter, a slight decrease in the final recovery at pH 3.0 was
measured, which could be associated with the formation of chains
or clusters, as seen by TEM, with a possible increased tendency to
aggregate under stress. At pH 5.0 both the recovery and the
colloidal stability were partially altered as reflected by insoluble
aggregates visualized. This was probably the result of interactions
between capsids that lost their native conformation due to
environmental conditions, a fact that deserves further attention.
At pH 8.0, the profile variation suggested the onset of dissociation
in addition to partial aggregation. On the other hand, the
association of the multimers in clusters or chains as visualized by
TEM analysis resembled a quite similar phenomenon of particle
adhesion described during large scale production of HCV core-like
particles in this yeast strain [53–55]. Heterogeneity of the
multimeric HBsAg and the formation of soluble aggregates during
recombinant production and purification from P. pastoris were also
previously documented [49]. At the end, the structure-dependent
quantification of RHDV VLP confirmed that pH 4 or 7 were
appropriate in terms of structure preservation and recovery
without an increase in heterogeneity of the particles.
Process steps like concentration/diafiltration, temperature
stresses and simulated storage provided useful data for production
Table 3. Hemagglutination inhibition titers detected in sera of rabbits immunized with the recombinant VLP and challenged with
RHDV.
Anti-RHDV hemagglutination inhibition titersa/Anti-RHDV ELISA inhibition percents [Mean 6 standard deviation]b
Days Yeast-derived VLP vaccine (n = 7)
VP1 (VP60) from insect cultured
cells (n = 3) Placebo (n = 3)
0 n.d. n.d. n.d.
Mean 10.462.5a 8.764.6a 9.462.8a
40 1/256 1/4096 1/16
1/1024 1/2048 1/16
1/256 1/1024 1/8
1/256
1/1024
1/512
1/128
Mean 91.561.6a 92.863.7a 10.164.6b
10 days post-challenge 1/1024 1/8192 –
1/2048 1/4096
1/512 1/4096
1/2048
1/2048
1/256
1/512
Mean 93.960.7a 94.261.4a –
Survival after 102LD50 RHDV challenge 100% 100% 0
aThe HI titer was expressed as the maximum dilution capable to completely inhibit the agglutination of human type O erythrocytes by RHDV. Each titer value
corresponds to an individual animal. In the assay, a hyperimmune serum against RHDV (with an HI titer of 1/2048) was used as positive control. All animals were
immunized at days 0 and 21. n.d.: hemagglutination inhibition titers not detected.
bThe result is also expressed as the mean 6 standard deviation of inhibition values obtained in cELISA from individual animals. Different letters within a row indicate
statistical significant differences for p,0.05, according to the Kruskal-Wallis and Dunn’s tests.
doi:10.1371/journal.pone.0056417.t003
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purposes. Volume concentration, buffer changing and sterile
filtration constitute obligatory steps in order to attain the antigen
concentration and sterility needed within the aqueous and oily-
based formulations. However, phase changes as those provoked by
storage at 220uC (freezing/thawing stress) or variations induced
by long-term storage of the active raw material at 4uC could be
avoided following a fermentation-to-adjuvantation uninterrupted
production process as designed in our own production facilities for
available vaccines [41,26,56].
With regard to the use of additives (if storage in solution for long
periods is required), they must warrant the preservation of native
conformational epitopes, the multimeric nature of the antigen and
better recovery rates after storage. The use of stabilizers
recognized as safe, like disaccharides sucrose and trehalose, or
sorbitol and glycerol have shown in the past to be a useful strategy
with inhibitory aggregation effects exerted by different mechan-
isms [57]. They are compounds known to be effective stabilizers of
the structure of proteins [58–61]. Here, the capacity of additives to
stabilize the VLP was concentration related and behaved similar at
both pH assayed. It is valid to note that previous studies concluded
that stabilizers of an antigen in solution give indeed formulations
with improved thermal stability of the antigen in the adsorbed
state [62,63]. More recent findings on these yeast-derived VLP
pointed as well to the utility of glucose 25% as inhibitor of
aggregation under accelerated conditions at 60uC [64]. Based on
the findings here described, it is also possible that other FDA-
approved stabilizers could produce similar results.
A RHDV VLP-based vaccine is needed to be physically and
thermally stable. Under these conditions antigen integrity within
the formulation and maintenance of immunogenic capacity are
highly relevant. Managing of veterinary vaccination has draw-
backs like the necessity to deal with great numbers of animals
along with laborious and stressing manipulation. In countries with
subtropical or tropical climates there are also frequent cold-chain
changes that result in thermal stresses. Here, the antigen integrity
within the samples kept at 48uC was only slightly affected at the
multimeric form level, thus generating a portion of disassembled
(monomeric or dimeric) molecules. Even though no obvious
changes were seen by TEM, heterogeneous populations must have
been present, a fact that can be assessed by determination of
diffusion coefficients and hydrodynamic sizes. Nevertheless, no
differences were observed in the specific antibody response
generated in the groups of rabbits injected with the stressed
samples. The magnitude of the response reached was known to be
sufficient to protect rabbits against RHDV [65]. As stability of
RHDV VLP was only approached from a biochemical/antigenic
perspective future work will deepens on stability under variable
conditions using biophysical approaches and high resolution
techniques.
The capacity to protect rabbits challenged with RHDV ensured
the validity of the process from a clinical point of view. Also, the
immunogenicity evidenced with formulations treated at 37 and
48uC agreed with the stability proved and supports the field use.
The feasibility of using these multimers in a single dose regimen
was also demonstrated. The ability to protect at even smaller doses
Table 4. Hemagglutination inhibition titers detected in sera of rabbits vaccinated with different doses or different VLP
concentrations per dose.
Anti-RHDV hemagglutination inhibition titersa/Anti-RHDV ELISA inhibition percents [Mean 6 standard deviation]b
Days
Two doses
50 mg
Two doses
25 mg
Two doses
10 mg Two doses 5 mg One dose 50 mg One dose 25 mg Placebo
0 n.d. n.d n.d n.d. n.d n.d. n.d.
Mean 7.262.5a 5.863.4a 11.464.1a 9.862.2a 6.965.7a 4.263.5a 10.364.2a
40 1/64 1/128 1/256 1/32 1/128 1/128 n.d.
1/512 1/128 1/128 1/32 1/1024 1/128
1/128 1/64 1/16 1/32 1/128 1/64
1/128 1/128 1/32 1/64 1/128 1/128
1/512 1/128 1/32 1/8 1/128 1/64
1/128 1/32 1/32 1/8 1/64 1/128
Mean 90.461.4a 88.761.5a 85.463.1a 8867.9a 90.962.7a 88.161.6a 8.665.3b
60 1/128 1/128 1/128 1/32 1/128 1/128 n.d.
1/128 1/128 1/64 1/16 1/1024 1/128
1/512 1/128 1/32 1/16 1/128 1/64
1/128 1/128 1/8 1/64 1/128 1/128
1/512 1/512 1/16 1/16 1/128 1/32
1/128 1/64 1/16 1/16 1/64 1/128
Mean 91.161.9a 89.662.5a 87.864.5a 85.365.6a 91.161.8a 89.560.7a 7.364.7b
aThe HI titer was expressed as the maximum dilution capable to completely inhibit the agglutination of human type O erythrocytes by RHDV. Each titer value
corresponds to an individual animal. In the assay, a hyperimmune serum against RHDV (with an HI titer of 1/2048) was used as positive control. All animals were
immunized at days 0 and 21. n.d.: hemagglutination inhibition titers not detected. bThe result is also expressed as the mean 6 standard deviation of inhibition values
obtained from individual animals in cELISA. Different letters within a row indicate statistical significant differences for p,0.05, according to the Kruskal-Wallis and
Dunn’s tests.
doi:10.1371/journal.pone.0056417.t004
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has been previously assayed and found viable by authors that
employed valuable expression systems though with less potential
for production at large scale.
On this matter, single step purification by size exclusion
chromatography using Sepharose CL4B appears a promising
approach in terms of cost-effectiveness for large-scale production
in detriment of ultrafiltration-based techniques. Results from the
10-L culture and purification processes are encouraging. Extrap-
olating the 10-L approach, and considering our own experience on
cell growing experiments with this yeast strain and products
derived from it [47,48,66,25,26] suggest that for instance, a 50-L
culture will allow obtaining a final biomass of approximately
12.5 Kg wet weight, meaning 20.8 liters of cell material to disrupt
(at 600 g/L) and about 44.6 liters of clarified disruption
supernatant. Such quantities are also suitable to be processed in
a 300 mm width61000 mm height purification column. Under
those conditions (column volume of 70686 mL), fifteen runs of
2827 mL each could be applied (4% charge) to render one peak
per run containing approximately 860 mg of protein properly
assembled. One day of purification may stand for nine runs, and
one single process should produce over 257410 doses if formulated
at 50 mg/mL. Moreover, at least three rounds could be conducted
per packed column considering a 200-L culture. The latter would
imply approximately 180 runs and a final production yield of
around 2–2.5 million doses. An industrial process with related
manufacturing steps and handling procedures is already estab-
lished for the licensed GavacplusTM veterinary vaccine, produced at
CIGB facilities (HeberBiotec S.A.), aimed to fight ectoparasite
infestations in cattle with prospective use in dogs [41,67,56]. At
present, safety evaluation of RHDV VLP in rabbits, according to
harmonized guidelines from VICH, has demonstrated both safety
and efficacy under field conditions [68].
Expression levels of VP1, always over 300 mg per liter of
culture, constitute an authentic advantage to consider this system
Figure 5. RHDV VLP as carriers for immunization against CSFV. (A) SDS-PAGE of conjugation of E2 peptide to the VLP. The 24 amino acids
linear peptide from CSFV E2 glycoprotein was synthesized with purity over 95% and coupled to RHDV VLP. The gel was loaded with the synthetic E2
peptide (lane 1), VP1 conjugated to E2 peptide (lane 2) and unconjugated VP1 (lane 3). Numbers in the left and marker bands indicate the migration
of standard molecular weight markers. (B) Antibody response generated in vaccinated pigs. Animals immunized twice with the E2 peptide
conjugated to RHDV VLP showed the highest IgG peptide-specific titers, which were statistically superior to those obtained in the rest of the groups.
Titers were expressed as the inverse of the maximum serum dilution having an OD superior to the negative control mean OD. (C) Antibodies able to
react against the whole recombinant E2 protein were detected in the peptide immunized groups. (D) Antibodies with the capacity to compete for
binding to RHDV were also detected by a modified cELISA in vaccinated pigs. For the analysis, an ANOVA was employed and mean titers were
compared using the Newman-Keuls Multiple Comparison test. Statistical differences of the group immunized with the E2 peptide conjugated to VLP
were indicated with one (p,0.05) or two (p,0.01) asterisks. Standard deviation bars are also shown.
doi:10.1371/journal.pone.0056417.g005
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for vaccine production even if the target is a small animal species.
Recently, the potential of VLP, and specifically RHDV VLP
obtained from insect cells, to induce humoral and cell-mediated
immune responses against foreign epitopes incorporated by
genetic fusion or chemical conjugation has been shown in
successful experiments [31–33]. On this sense, it was recently
reported the generation of specific responses in pigs by chimeric
RHDV VLP (obtained from Trichoplusia ni cells) carrying a T-cell
epitope of the 3A protein from foot-and-mouth disease virus
(FMDV) [34]. In the present work, we used highly stabilized VLP
obtained at elevated recovery rates as carriers against a relevant
disease in pigs employing a B-cell epitope attached by chemical
conjugation.
Our group has also developed a recombinant subunit vaccine
candidate against CSFV that currently undergoes developmental
stages [39,69,70]. This candidate is based on the expression of the
E2 antigen in the milk of non-transgenic goats [70]. However,
various groups have informed on the existence of B-cell
neutralizing linear epitopes within the E2 sequence that protected
pigs to variable extents against CSFV challenges [42,71,72]. Here,
VP1 multimers were shown to successfully present one B-cell
protective epitope to the immune system of pigs and enhance the
IgG specific antibody response against this peptide. Chemical
coupling has shown in the past to allow high peptide loads per
VLP [31]. Our experiment compared the effect of the attached
peptide with the immunogenicity of the peptide alone, the peptide
co-administered with the VLP and with the response generated by
the entire E2 recombinant protein. The presence of antibodies in
animals immunized with the peptide fragment with the ability to
react against the whole E2 recombinant protein was seen, to our
knowledge, for the first time in pigs. Conversely, very recent
reports have suggested the use of this fragment in combination
with others in order to increase the protective efficacy [73,74].
Other authors for instance, give attention to peptides covering
amino acids 829 to 837 or 844 to 865 used under more
immunogenic presentations [72,73,75]. Whether this fragment
could be the most immunogenic or fully protective against CSFV
will require challenge trials in which more experimental groups,
fragment combinations and displaying strategies are considered.
One interesting issue is that with the use of one of these epitopes,
cell-mediated specific immune responses appeared to correlate
with partial protection in pigs in the absence of neutralizing
antibodies [74]. Thus, an ideal strategy would consider one or
more B-cell (and T-cell) epitope for presentation. In summary,
another element was provided to encourage the use of these
multimers beyond the boundaries of vaccination against RHD,
specifically for use in larger animals.
Many advantages and also limitations have been reviewed with
regard to VLP modification and their use, including concerns on
large-scale production, process control and optimization [76–79].
As VLP vaccines for humans are nowadays a reality [78,29], the
coupling or insertion of heterologous fragments with the intention
of widen their practical value, along with technological improve-
ments, must be a permanent research focus. Given the relevance
of these trends, the establishment of an efficient platform to allow
production/implementation of this kind of vaccine became an
objective of this work. The results presented, and the knowledge
gathered so far, support our endeavour to easily produce at large-
scale safe, cost-effective RHDV VLP antigenically similar to
RHDV, which may also be useful for additional purposes
pertaining animal or human health. Future work will add to these
results the parameters and requirements needed for recombinant
vaccine production meant for use in human populations.
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